Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26659483 | 0.94 | KEAP1 (0.56) | KEAP1NFE2L2MAOBAPP | |
| Hydrochloric Acid SCHEMBL26601051 | 0.93 | MAOB (0.54) | KEAP1NFE2L2MAOBAPP | |
| SCHEMBL7973439 | 0.89 | KEAP1 (0.67) | KEAP1NFE2L2MAOBST14LTA4H | |
| SCHEMBL8339774 | 0.84 | MAPT (0.52) | LTA4H | |
| SCHEMBL6568884 | 0.84 | TAAR1 (0.62) | MAOB | |
| SCHEMBL17321130 | 0.83 | LTA4H (0.52) | APPLTA4H | |
| SCHEMBL7388158 | 0.82 | KEAP1 (0.64) | KEAP1NFE2L2MAOBST14LTA4H | |
| SCHEMBL7988040 | 0.82 | KEAP1 (0.64) | KEAP1NFE2L2MAOBST14LTA4H | |
| SCHEMBL2560922 | 0.81 | MAOB (0.53) | KEAP1NFE2L2MAOB | |
| SCHEMBL873831 | 0.81 | TAAR1 (0.48) | MAOBLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-02 | — | — | US | disclosed |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-25 | — | — | US | disclosed |
| CN-117529472-A | GPR35 agonist compounds | 赫普泰雅治疗有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-4069223-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | Anakuria Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | US | disclosed |
| WO-2021113665-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2900633-A1 | ALPHA HYDROXY AMIDES | Merck Patent GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-0276631-B1 | WETTABLE SURFACE MODIFIED CONTACT LENS FABRICATED FROM AN OXIRANE CONTAINING HYDROPHOBIC POLYMER | CIBA-GEIGY AG (CH) | 1991-05-29 | — | — | EP | disclosed |
| EP-0276631-A1 | Wettable surface modified contact lens fabricated from an oxirane containing hydrophobic polymer | CIBA-GEIGY AG (CH) | 1988-08-03 | — | — | EP | disclosed |
| US-4734475-A | Wettable surface modified contact lens fabricated from an oxirane containing hydrophobic polymer | CIBA-GEIGY CORPORATION (US) | 1988-03-29 | — | — | US | disclosed |
| US-4634701-A | Furan derivatives having anti-ulcer activity | AUSONIA FARMACEUTICI S.R.L. (IT) | 1987-01-06 | — | — | US | disclosed |
| EP-0164040-A2 | Furan derivatives having anti-ulcer activity | AUSONIA FARMACEUTICI S.r.l. (IT) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186935-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | KEAP1 1760/4885NFE2L2 4610/4885MAOB 4115/4885 |
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | KEAP1 1760/4885NFE2L2 4610/4885MAOB 4115/4885 |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | KEAP1 1760/4885NFE2L2 4610/4885MAOB 4115/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | KEAP1 937/4885NFE2L2 3995/4885MAOB 4268/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | KEAP1 924/4885NFE2L2 346/4885MAOB 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.